TRIMTECH lands $411M Biogen deal for neurodegeneration protein degraders

Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal could bring TRIMTECH up to $411 million (about €373 million), plus royalties.

ADVERTISEMENT

Why it matters: The partnership adds another major pharmaceutical company to the growing list of players investing in targeted protein degradation. TRIMTECH is pursuing an especially challenging application: clearing toxic protein aggregates associated with neurodegenerative diseases while preserving the proteins needed for normal cellular function.

The deal: TRIMTECH could receive up to $32 million (about €29 million) in upfront and research milestone payments. The total potential value reaches $411 million, including later milestones.

Biogen will collaborate on drug discovery and has an option to obtain exclusive global rights to the resulting degraders. If it exercises the option, Biogen will take responsibility for further development and commercialization.

The partners have not disclosed the specific targets, indications or amount payable upfront.

How it works: Most targeted protein degraders work by recruiting an E3 ligase, an enzyme that helps mark unwanted proteins for destruction by the cell’s disposal machinery.

TRIMTECH uses TRIM21, an E3 ligase whose activation depends on protein clustering. Its TRIMTAC and TRIMGLUE platforms aim to exploit this property to selectively remove toxic protein aggregates and oligomers while leaving the normal, individual forms of the proteins intact.

The technology builds on research by TRIMTECH co-founders Leo James and William McEwan. A 2025 study published in Nature Communications showed that TRIMTAC molecules could inhibit the spread of tau aggregation in cultured cells and mouse neurons, including under conditions where a conventional PROTAC comparator was ineffective. TRIMTECH also says its degraders can reach the central nervous system, an important requirement for treating brain diseases. These findings remain preclinical, however.

Backstory: Founded in 2023, TRIMTECH extended its seed financing to $47 million (about €43 million) in June, attracting investors including Johnson & Johnson Innovation and BGF. Pfizer Ventures and Eli Lilly were already among its backers.

The big picture: Biogen’s agreement follows a series of investments and partnerships involving small-molecule degraders, including several focused on neurological diseases.

  • Oyster Therapeutics: Just last week, the London-based biotech raised $60 million to advance an oral tau degrader for Alzheimer’s disease. Its SELFTAC technology aims to overcome the brain-penetration limitations of conventional bifunctional degraders.
  • Ipsen: In February, the French drugmaker partnered with U.S.-based Origami Therapeutics to develop small-molecule degraders for a rare inherited neurodegenerative disorder.
  • Roche: In October, the Swiss pharma group struck a deal with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases. The agreement was reportedly worth close to $1 billion, although financial terms were not officially disclosed.

The interest extends to related ways of eliminating disease-driving proteins. Also in October, Pfizer partnered with France’s Enodia Therapeutics in a deal potentially worth more than $500 million. Enodia takes a different approach, preventing selected proteins from being produced rather than degrading them after synthesis.

What to watch: While dealmaking is accelerating, the neurological applications of targeted protein degradation remain largely at the research stage. Brain penetration, selectivity and clinical efficacy still need to be established.

For TRIMTECH, the next milestone will be turning its research platform into defined drug candidates. For Biogen, the agreement provides another way to explore protein clearance in neurodegeneration without committing immediately to full development.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!